NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Leo I. Gordon(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Julie Chang(University of Wisconsin Carbone Cancer Center), Beth Christian(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jeremy S. Abramson(Massachusetts General Hospital), Ranjana H. Advani(Cancer Institute (WIA)), Nancy L. Bartlett(Barnes-Jewish Hospital), Lihua E. Budde(City Of Hope National Medical Center), Paolo F. Caimi(Cleveland Clinic), Sven de Vos(University of Colorado Cancer Center), Bhagirathbhai Dholaria(Breast Cancer Research Foundation), Bita Fakhri(UCSF Helen Diller Family Comprehensive Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Martha Glenn(University of Utah), Thomas M. Habermann, Francisco J. Hernandez‐Ilizaliturri, Eric D. Hsi(Cleveland Clinic), Boyu Hu(University of Utah), Mark Kaminski(University of Michigan), Chris R. Kelsey(Cancer Institute (WIA)), Nadia Khan(Fox Chase Cancer Center), Susan Krivacic, Ann S. LaCasce(Dana-Farber Brigham Cancer Center), Megan S. Lim(University of Pennsylvania), Mayur Narkhede(University of Colorado Cancer Center), Rachel Rabinovitch(University of Colorado Cancer Center), Praveen Ramakrishnan(Southwestern Medical Center), Erin Reid(University of California San Diego), Kenneth B. Roberts(Smilow Cancer Hospital), Hayder Saeed(Moffitt Cancer Center), Stephen D. Smith(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jakub Svoboda(University of Pennsylvania), Lode J. Swinnen(Sidney Kimmel Comprehensive Cancer Center), Joseph M. Tuscano(UC Davis Comprehensive Cancer Center), Julie M. Vose(Susan Thompson Buffett Foundation), Mary A. Dwyer(National Comprehensive Cancer Network), Hema Sundar(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
November 1, 2021
10.6004/jnccn.2021.0054
Cited by 170Open Access
Full Text

Abstract

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

Related Papers

No related papers found

Powered by citation graph analysis